Current Opinion in Supportive and Palliative Care, 9 (2), 189195
A previous study identified that there was significantly higher EAT level and severe myocardial damage in HFpEF patients with atrial fibrillation and/or T2DM [86]
This could have a huge population impact in terms of reducing morbidity and mortality from cardiovascular disease. Whats impressive about the risk reduction seen with semaglutide is that trial participants were reasonably well-treated for CVD, Martha Gulati, MD (Smidt Heart Institute at Cedars-Sinai, Los Angeles, CA), president of the American Society for Preventive Cardiology, commented to TCTMD via email
The GLP-1 advantage: These medications simultaneously address 34 of these obesity types at once
Many of our Scottsdale patients pair them with MIC lipotropic injections for added fat-metabolism support, IV therapy and vitamin drips for full-body hydration and nutrient replenishment, or our Tri-Immune Boost for extra immune defense
Additionally, semaglutide GLP-1 injections, when given under medical supervision, can also help to reduce appetite, leading to weight loss